Plerixafor (Standard)

Plerixafor (AMD 3100; JM3100; SID791) (Standard) is the analytical standard of Plerixafor (AMD 3100; JM3100; SID791) (HY-10046). This product is intended for research and analytical applications. Plerixafor (AMD 3100; JM3100; SID791) is a CXCR4 antagonist and a CXCR7 allosteric agonist; Plerixafor disrupts stem cell retention in the bone marrow by blocking the SDF-1α/CXCL12‑CXCR4 signaling pathway and inhibiting chemokine-mediated receptor internalization, mobilizing peripheral blood leukocytes, neutrophils, endothelial progenitor cells, and B cells; Plerixafor alleviates Silicon dioxide (HY-W019831)-induced pulmonary inflammation and fibrosis, inhibits corneal neovascularization and CXCL12-induced cell migration, and simultaneously suppresses ischemia-induced inflammatory responses, reduces blood-brain barrier permeability, attenuates cerebral edema, and reduces infarct volume. Plerixafor can be used in research related to liver fibrosis, silicosis, colorectal cancer, and ischemic stroke.